Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cypher $470 Mil. Q4 Domestic Sales Double Size Of Cordis Unit

This article was originally published in The Gray Sheet

Executive Summary

Cypher drug-eluting stent U.S. sales propelled a 99% Cordis revenue jump in the fourth quarter to $896 mil

You may also be interested in...



Taxus Clears Legal Hurdle As Judge Denies J&J/Cordis Injunction Request

The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson

Guidant To Seek Review Of $425 Mil. Patent Suit Arbitration Award To Cordis

Guidant stent sales will not be affected by a June 5 arbitration panel finding that the firm infringed Johnson &Johnson/Cordis' Palmaz-Schatz patents, Guidant says

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel